{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-257803","form_type":"8-K","ticker":null,"cik":"0001426332","company_name":"NGM BIOPHARMACEUTICALS INC","filed_at":"2023-10-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.035233+00:00","generated_at":"2026-06-09T22:31:58.072245+00:00","sec_items":["5.02"],"event_type":"other","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NGM Biopharmaceuticals reprices underwater stock options for employees, effective after Q3 2023 filing","bullets":["Compensation Committee approved repricing of 7,037,470 eligible options with exercise prices >$5.00 to closing price on Effective Date.","CEO David Woodhouse holds 2,449,846 options at original exercise prices $7.54-$31.93; options now deeply underwater (stock ~$1.02).","Eligible options subject to 12-18 month retention period; early exercise requires original higher strike price.","Outgoing President & CFO Siobhan Nolan Mangini's underwater options excluded from repricing; she departs Dec 1, 2023.","Repricing covers 88% of eligible options with original exercise prices from $7.54 to $31.93 per share."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-257803","json":"https://secwatch.observer/filing/0001193125-23-257803.json","markdown":"https://secwatch.observer/filing/0001193125-23-257803.md","text":"https://secwatch.observer/filing/0001193125-23-257803.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426332/000119312523257803/0001193125-23-257803-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426332/000119312523257803/d560739d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T22:31:58.072245+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7796046190","claim":"Siobhan Nolan Mangini departed as President and Chief Financial Officer at NGM BIOPHARMACEUTICALS INC.","evidence_excerpt":"Siobhan Nolan Mangini who, as previously announced by the Company, is stepping down as President and Chief Financial Officer on December 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1426332/000119312523257803/0001193125-23-257803-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepping down"},{"label":"Role","value":"President and Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}